Research
Hormonal
Beta-cell dysfunction and loss of functional mass are present at the time of Type 2 Diabetes diagnosis and progressively decline by approximately 5% annually, independent of disease duration.
Understand that beta-cell function naturally declines after diagnosis. This is not your fault, but it is a biological reality. The goal of management is to slow this decline by reducing the workload on your pancreas through weight management and lifestyle changes.
StrongSupportsHIGH confidence
Beta-cell dysfunction is present at the diagnosis of T2DM and progressively worsens with disease duration... beta-cell function... was already decreased by -50% at the time of diagnosis and progressively declined by -5% annually.
Why this rating
Supported by long-term prospective studies like UKPDS.
Source
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Yoshifumi Saisho · World Journal of Diabetes · 2015
DOI 10.4239/wjd.v6.i1.109
narrative_reviewCited 253×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Preserving or recovering beta-cell functional mass is the critical therapeutic strategy for preventing and managing type 2 diabetes, primarily achieved by reducing beta-cell workload through lifestyle modification and weight loss.Good
- Ethnicity influences beta-cell functional capacity, with Asians having lower beta-cell regenerative capacity and insulin secretion compared to Caucasians, leading to T2DM at lower BMI levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →